BlackRock
OLMA icon

BlackRock’s Olema Pharmaceuticals OLMA Stock Holding History

BlackRock’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84M Buy
6,714,691
+1,062,556
+19% +$14.2M ﹤0.01% 2327
2026
Q1 		$84.3M Buy
5,652,135
+88,875
+2% +$1.98M ﹤0.01% 2213
2025
Q4 		$139M Buy
5,563,260
+836,866
+18% +$14.9M ﹤0.01% 1902
2025
Q3 		$46.3M Buy
4,726,394
+121,285
+3% +$728K ﹤0.01% 2557
2025
Q2 		$19.6M Buy
4,605,109
+782,767
+20% +$3.49M ﹤0.01% 3039
2025
Q1 		$14.4M Buy
3,822,342
+32,510
+0.9% +$164K ﹤0.01% 3124
2024
Q4 		$22.1M Sell
3,789,832
-57,639
-1% -$576K ﹤0.01% 2985
2024
Q3 		$45.9M Sell
3,847,471
-152,047
-4% -$1.94M ﹤0.01% 2515
2024
Q2 		$43.3M Buy
3,999,518
+782,964
+24% +$8.49M ﹤0.01% 2497
2024
Q1 		$36.4M Sell
3,216,554
-47,353
-1% -$611K ﹤0.01% 2636
2023
Q4 		$45.8M Buy
3,263,907
+1,021,018
+46% +$13.7M ﹤0.01% 2529
2023
Q3 		$27.7M Sell
2,242,889
-90,411
-4% -$922K ﹤0.01% 2752
2023
Q2 		$21.1M Buy
2,333,300
+1,337,123
+134% +$8.07M ﹤0.01% 3009
2023
Q1 		$3.46M Sell
996,177
-47,018
-5% -$192K ﹤0.01% 3801
2022
Q4 		$2.56M Sell
1,043,195
-258,731
-20% -$755K ﹤0.01% 4024
2022
Q3 		$3.59M Sell
1,301,926
-3,578
-0.3% -$15.2K ﹤0.01% 3902
2022
Q2 		$5.31M Sell
1,305,504
-1,247,445
-49% -$3.96M ﹤0.01% 3791
2022
Q1 		$10.9M Buy
2,552,949
+254,785
+11% +$1.4M ﹤0.01% 3535
2021
Q4 		$21.5M Sell
2,298,164
-41,811
-2% -$866K ﹤0.01% 3231
2021
Q3 		$64.5M Buy
2,339,975
+870,796
+59% +$23.5M ﹤0.01% 2496
2021
Q2 		$41.1M Buy
1,469,179
+16,159
+1% +$460K ﹤0.01% 2830
2021
Q1 		$48.2M Buy
1,453,020
+768,311
+112% +$32.9M ﹤0.01% 2638
2020
Q4 		$32.9M Buy
+684,709
New +$32.1M ﹤0.01% 2733

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock's OLMA Position: Q2 2026 in Review

BlackRock increased its Olema Pharmaceuticals (OLMA) stake by 19% in Q2 2026, buying an estimated $14.2M and bringing the position to 6,714,691 shares worth $84M. The position accounts for ﹤0.01% of the portfolio, ranked #2327.

BlackRock first reported a position in OLMA in Q4 2020 and has held it in 23 quarters since. The position peaked at $139M in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • BlackRock held 6,714,691 shares of Olema Pharmaceuticals worth $84M as of Q2 2026.
  • BlackRock bought 1,062,556 Olema Pharmaceuticals shares in Q2 2026, an estimated $14.2M.
  • Olema Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2327 holding.
  • BlackRock first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's Olema Pharmaceuticals position peaked at $139M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.